Protease Inhibitors (Protease Inhibitor)

Subscribe to Selected New Research on Protease Inhibitors

3304 relevant articles (184 outcomes, 310 trials/studies) found for this Bio-Agent

Description: Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES).

Also Known As:

Protease Inhibitor; Antiproteases; Antagonists, Protease; Hydrolase Inhibitors, Peptide; Inhibitor, Protease; Inhibitors, Endopeptidase; Inhibitors, Peptidase; Inhibitors, Peptide Hydrolase; Inhibitors, Peptide Peptidohydrolase; Inhibitors, Protease; Peptidohydrolase Inhibitors, Peptide; Endopeptidase Inhibitors; Peptidase Inhibitors; Peptide Hydrolase Inhibitors; Peptide Peptidohydrolase Inhibitors; Protease Antagonists

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses

Pharmacologic Actions: 49

Molecular Mechanisms of Pharmacological Action: 5

Enzyme Inhibitors: 603

Protease Inhibitors: 3304

Angiotensin-Converting Enzyme Inhibitors: 7072

HIV Protease Inhibitors: 186

Serine Proteinase Inhibitors: 157

Cysteine Proteinase Inhibitors: 100

Dipeptidyl-Peptidase IV Inhibitors: 11

Experts

1.	Fischl, Margaret A: 3 articles (06/2007 - 10/2003)
2.	Vicente, Vicente: 3 articles (04/2007 - 05/2005)
3.	Corral, Javier: 3 articles (04/2007 - 05/2005)
4.	Otsuki, Makoto: 3 articles (01/2007 - 01/2005)
5.	Takeda, Kazunori: 3 articles (01/2007 - 11/2004)
6.	Chêne, G: 3 articles (05/2006 - 12/2000)
7.	Suzuki, Mika: 3 articles (02/2004 - 03/2002)
8.	Kobayashi, Hiroshi: 3 articles (02/2004 - 03/2002)
9.	Kanayama, Naohiro: 3 articles (02/2004 - 03/2002)
10.	Terao, Toshihiko: 3 articles (02/2004 - 03/2002)

Related Diseases

1.	Pancreatitis 11/01/1999 - "These results indicate that intraperitoneal leakage of PLA2 plays an important role in bacterial translocation during acute pancreatitis and that administration of a protease inhibitor may be effective against the bacterial translocation." 01/01/2007 - "Additional research is needed to confirm the preventive efficacy of these antiproteases in patients at a high risk of developing post-ERCP pancreatitis." 10/01/2000 - "Therapeutic efficacy of continuous arterial infusion of an antibiotic and a protease inhibitor via the superior mesenteric artery for acute pancreatitis in an animal model." 04/01/2008 - "OBJECTIVES: Protease inhibitors showed protective effects on animal models of acute pancreatitis when administered before induction of pancreatitis, and results when administered after induction are uncertain. " 01/01/2009 - "This study provides a clear rationale for further research to investigate the efficacy of enteral protease inhibitors in the treatment of acute pancreatitis." Order ALL the reference details at left...
2.	Acquired Immunodeficiency Syndrome (AIDS) 07/01/2004 - "CONCLUSIONS: Although new treatments have significantly improved the physical health of those living with HIV/AIDS, no evidence was found that these treatments significantly improved psychological health for women, regardless of history of protease inhibitor use." 02/01/2002 - "Protease inhibitor combination therapies have significantly improved the health of many people with HIV/AIDS. " 09/01/1997 - "The safety and efficacy of two successive sessions of WBHT (4 days apart) was evaluated in 30 patients with AIDS (not on protease inhibitors), randomized to: 1) untreated controls, 2) low temperature WBHT for 1 hour at 40 degrees C and repeated 96 hours later, and 3) high temperature WBHT for 1 hour at 42 degrees C and repeated 96 hours later. " 07/01/1997 - "In order to test the hypothesis that a combination of protease inhibitors with nucleoside analogues-agents known to inhibit different steps of the human immunodeficiency virus (HIV) life cycle--is likely to prove more effective in reducing viral loads than either of those modalities alone, we performed a 60 week, open-label trial in 32 HIV-positive patients with depressed CD4 T lymphocyte cell counts but no active AIDS-defining illnesses. " 10/01/2008 - "Therefore, the incomplete suppression of HIV in treatment-experienced AIDS patients will continue to drive the search for more effective therapeutic agents that exhibit efficacy against the mutants raised by the earlier generation of protease inhibitors. " Order ALL the reference details at left...
3.	HIV Infections (HIV Infection) 08/01/2007 - "BACKGROUND: Protease inhibitors were a major therapeutic breakthrough in the mid-1990s for the treatment of HIV infection, which resulted in improved life expectancy for patients who had failed previous therapies. " 05/12/1999 - "BACKGROUND: Combination antiretroviral therapy including protease inhibitors (combo+PI) is effective in suppressing systemic viral load in HIV infection, but its impact on HIV-associated cognitive impairment is unclear. " 03/01/2003 - "Having changed the landscape in the treatment of HIV infection, the functional efficacy of current protease inhibitors (PIs) remains limited by their pharmacokinetic and pharmacodynamic profiles. " 02/01/1999 - "The advent of improved medical therapy with multidrug HIV medicines including protease inhibitors has prolonged life expectation of patients with HIV infection. " 02/10/1996 - "Protease inhibitors show promise in HIV infection." Order ALL the reference details at left...
4.	Infection 10/11/1999 - "Human immunodeficiency virus 1 (HIV-1) protease inhibitors have dramatically reduced the morbidity and mortality due to HIV-1 infection. " 10/27/2006 - "The introduction of human immunodeficiency virus type 1 (HIV-1) protease inhibitors (PIs) markedly improved the clinical outcome and control of HIV-1 infection. " 11/01/1998 - "Protease inhibitors' advantages are that they are effective against cells with HIV in different stages of infection, they are potent, and they work well with the other two classes mentioned. " 05/01/1999 - "Stanford University researchers have determined that protease inhibitors are effective against HIV-1 subtype C infections. " 09/01/2000 - "The danish protease inhibitor study: a randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 infection." Order ALL the reference details at left...
5.	Neoplasms (Cancer) 01/01/1987 - "The tasks remaining are to determine the kind and the level of protease inhibitors that are most effective in preventing cancer without also having toxic side effects and to incorporate them into our diet. " 10/14/1994 - "Epidemiological studies suggest that human populations consuming diets rich in protease inhibitors have a reduced incidence of cancer at several sites including the breast. " 08/01/1985 - "Protection against dimethylhydrazine-induced adenomatous tumors of the mouse colon by the dietary addition of an extract of soybeans containing the Bowman-Birk protease inhibitor." 03/01/2006 - "However, clinical trials using protease inhibitors have thus far been unsuccessful except for a few applications of matrix metalloprotease (MMP) inhibitors when used in combination with cytostatic anticancer agents and/or in the early stages of cancer. " 06/01/1998 - "Much of this review is focused on the characteristics of BBI as the anticarcinogenic protease inhibitor, as this is the protease inhibitor that has risen to the human trial stage as a human cancer chemopreventive agent. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Ritonavir (Norvir)
2.	Gabexate (Foy)
3.	Caerulein (Ceruletide)
4.	Reverse Transcriptase Inhibitors
5.	Indinavir (Crixivan)
6.	nafamostat
7.	Protease Inhibitors (Protease Inhibitor)
8.	ONO 3307
9.	RNA (Ribonucleic Acid)
10.	urinastatin (MR 20)

Related Therapies and Procedures

1.	Highly Active Antiretroviral Therapy (HAART)
2.	Intra-Arterial Infusions
3.	Drug Therapy (Chemotherapy)
4.	Ligation
5.	Oral Administration

Best Treatments:
Research Summary Report
on Pancreatitis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 711 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>